Τhe European Partnership One Health AMR should allow coordinating, aligning of activities and funding among countries in the EU and beyond, as well as facilitating national coherence on research and innovation between different services/ministries with responsibility for the various aspects of AMR and sectors involved (e.g. human and animal health, agriculture, environment, innovation).

This Partnership should also contribute to achieving the objectives of the Pharmaceutical Strategy for Europe, in terms of fulfilling unmet medical needs on AMR and ensuring that the benefits of innovation reach patients in the EU, and support the objectives of the new EU4Health Programme, as well as supporting the objectives of the Farm to Fork Strategy.

Thanks to its capacity to bring together different stakeholders (e.g. research funders, health authorities, citizens, healthcare providers, innovators, policymakers), the Partnership will create a critical mass of resources and implement a long-term Strategic Research and Innovation Agenda (SRIA).

The co-funded European Partnership on One Health AMR should be implemented through a joint programme of activities ranging from coordinating transnational research efforts to other activities such as coordination and networking activities, capacity building programmes, brokerage and mobility programmes, work on research infrastructures and resources, including training and dissemination activities.

The implementation of the future European Partnership on OH AMR should contribute to build a European Research and Innovation Area (ERA) to rapidly and jointly support research and innovation in the fight against AMR.

It should be structured along the following 3 main objectives:

• Collaboration and alignment of Research and Innovation agendas on OH AMR
• Boost Research and Innovation
• Enhance knowledge translation and uptake

The partnership should also:

Strengthen the OH AMR ecosystem with integrating activities engaging key actors for AMR encompassing the field of human, veterinary and environmental disciplines and the broad spectrum of pathogens, including fungi and viruses.

Establish robust communication and effective information exchange between diverse scientific disciplines and among multiple sectors of the society (as patients, clinicians, veterinarians, pharmacists, food producers, pharmaceutical industry, policymakers and researchers (including those working in the socio-economic, social sciences and humanities).

The Partnership’s governance structure should engage upfront the relevant actors to coordinate, steer and frame the research and innovation activities, facilitate the use and uptake of the results and contribute to a science-based communication of the risk of spread of AMR. The Partnership’s governance and operational structures should also foster a dialogue on sustainability, beyond funding from EU research and innovation framework programmes.